FDA’s Sunscreen Regulatory Approach Misaligned With Its Public Health Messaging, Trade Groups Say

The Personal Care Products Council and Consumer Healthcare Products Association say FDA’s tentative final sunscreen monograph and related communications have given rise to confusion that could lead to reduced sunscreen use and negative public health consequences. The groups go one further: FDA should reissue a tentative final monograph proposing that the 12 chemical UV filters currently in question are GRASE.

view of three wooden directional signs on a pole - Image

Since the US Food and Drug Administration issued its tentative final monograph for OTC sunscreen drug products in February, designating 12 currently marketed chemical UV filters as Category III (additional data needed), the media has been awash with headlines reflecting various reads on the proposed rule’s significance.

Interpretations among public health advocates include “FDA Admits Most Sunscreens Are Probably Unsafe,” while the Environmental Working Group received...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Regulation

US FDA Maintaining Approval Output Despite Losing Staff

 

Reviewers were not targeted by the FDA reduction in force, but increasing attrition and difficulties hiring new staff still do not seem to have impacted new and generic drug approval totals.

German Quaternary Wastewater Treatment Cost Estimates ‘Not Realistic’

 
• By 

Updating wastewater treatment facilities in Germany will cost almost three times more than the German Association of Local Public Utilities (VKU) has predicted, according to a Pharma Deutschland analysis.

New US FDA CDER Director Pledges No Politics In Approvals, Adds Higher Ups Can Overturn

 

New CDER Director George Tidmarsh promised to keep politics out of drug approvals, but suggested during a meeting with staff that he could not insulate the drug center from political pressures coming from those above him.

New US FDA Chief Counsel More Familiar With Trump World Than Food and Drug Law

 

Sean Keveney is largely unknown in the FDA law space, but likely is familiar and connected to the White House given his work on Trump’s antisemitism taskforce.

More from Policy & Regulation

New US FDA CDER Director Pledges No Politics In Approvals, Adds Higher Ups Can Overturn

 

New CDER Director George Tidmarsh promised to keep politics out of drug approvals, but suggested during a meeting with staff that he could not insulate the drug center from political pressures coming from those above him.

FDA Whips Up Sunscreen Delivery Format Warnings To Firms In US, Israel, Sweden

FDA admonishes five marketers for straying from approved sunscreen dosage forms in recent warning letters. Violative delivery formats render products unapproved drugs and misbranded.

Inspection Readiness 101: Prepare To Avoid Common Pitfalls When The FDA Comes Knocking

 

A panel of regulatory pros offered stakeholders tips for avoiding FDA citations after facility inspections. The July 29 webinar, hosted by ProPharma and Hyman Phelps and McNamara, follows the agency’s May announcement that it plans to up random foreign inspections.